Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 9/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12239025 | 0.94 | ST14 (0.61) | ST14MAOBKEAP1NFE2L2HRH3 | |
| SCHEMBL29673211 | 0.85 | ST14 (0.45) | ST14MAOBKEAP1NFE2L2HRH3 | |
| SCHEMBL1049645 | 0.83 | TAAR1 (0.61) | MAOBTAAR1 | |
| SCHEMBL30967134 | 0.83 | MAOB (0.47) | ST14MAOBKEAP1NFE2L2HRH3 | |
| SCHEMBL197077 | 0.81 | ELANE (0.50) | PPARGPPARA | |
| Hydrochloric Acid SCHEMBL14157305 | 0.81 | TAAR1 (0.59) | MAOBTAAR1 | |
| SCHEMBL26746 | 0.80 | SLC6A2 (0.44) | PPARGPPARA | |
| SCHEMBL19015929 | 0.79 | SLC6A4 (0.63) | TAAR1 | |
| SCHEMBL507215 | 0.79 | MAOB (0.45) | ST14MAOBKEAP1NFE2L2HRH3 | |
| SCHEMBL18266508 | 0.79 | ST14 (0.48) | ST14MAOBKEAP1NFE2L2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0064702-B1 | 4-TERT.-BUTOXYBENZYL AMINES | BASF Aktiengesellschaft (DE) | 1984-05-02 | — | — | EP | claimed |
| EP-0064702-A1 | 4-Tert.-butoxybenzyl amines | BASF Aktiengesellschaft (DE) | 1982-11-17 | — | — | EP | claimed |
| EP-4635568-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA Pharmaceuticals Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4622966-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-3672954-B1 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-06-19 | — | — | US | disclosed |
| CN-116354923-B | Nitrogen-containing heterocyclic compound and application thereof | 江苏恩华药业股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250032573-A1 | IMMUNITY-ENHANCING PEPTIDE ANALOGS AND USES THEREOF | Research & Business Foundation Sungkyunkwan University (KR) | 2025-01-30 | — | — | US | disclosed |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-7244849-B2 | Process for preparing a thiazole PPAR-ligand and polymorphs thereof | GLAXO GROUP LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| EP-0064702-B1 | 4-TERT.-BUTOXYBENZYL AMINES | BASF Aktiengesellschaft (DE) | 1984-05-02 | — | — | EP | disclosed |
| EP-0064702-B1 | 4-TERT.-BUTOXYBENZYL AMINES | BASF Aktiengesellschaft (DE) | 1984-05-02 | — | — | EP | disclosed |
| EP-0064702-A1 | 4-Tert.-butoxybenzyl amines | BASF Aktiengesellschaft (DE) | 1982-11-17 | — | — | EP | disclosed |
| EP-0064702-A1 | 4-Tert.-butoxybenzyl amines | BASF Aktiengesellschaft (DE) | 1982-11-17 | — | — | EP | disclosed |
| EP-0064702-A1 | 4-Tert.-butoxybenzyl amines | BASF Aktiengesellschaft (DE) | 1982-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | ST14 1293/4885MAOB 1390/4885KEAP1 1256/4885 |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | ST14 2999/4885MAOB 459/4885KEAP1 426/4885 |
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | ST14 2171/4885MAOB 773/4885KEAP1 4210/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | ST14 1344/4885MAOB 1341/4885KEAP1 1379/4885 |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | ST14 2999/4885MAOB 459/4885KEAP1 426/4885 |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, PCSK9, ALPI | ST14 834/4885MAOB 1191/4885KEAP1 1679/4885 |
| US-20250032573-A1 | IMMUNITY-ENHANCING PEPTIDE ANALOGS AND USES THEREOF | FPR3, FPR1, FPR2 | ST14 1049/4885MAOB 3805/4885KEAP1 2927/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | ST14 2171/4885MAOB 773/4885KEAP1 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.